Blue Jet Healthcare Ltd (NSE: BLUEJET) and Syngene International Ltd. (NSE: SYNGENE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Blue Jet Healthcare has a market capitalisation of ₹9,353 Cr and Syngene International ₹16,439 Cr, as of 9 Nov 2026. Their P/E ratios are 34.6 and 52.5 respectively. Return on equity is 19.88% for Blue Jet Healthcare and 6.62% for Syngene International. Over one year, Blue Jet Healthcare's share price is down 19.6% and Syngene International's is down 33.7%.
| Metric | Blue Jet Healthcare | Syngene International |
|---|---|---|
| NSE Symbol | BLUEJET | SYNGENE |
| BSE Code | 544009 | 539268 |
| Share Price | ₹541.90 | ₹436.00 |
| Market Cap | ₹9,353 Cr | ₹16,439 Cr |
| P/E Ratio | 34.6 | 52.5 |
| Return on Equity | 19.88% | 6.62% |
| Return on Assets | 11.24% | 4.78% |
| Dividend Yield | 0.24% | 0.30% |
| Beta (1Y) | 0.89 | -0.08 |
| 1-Year Price Change | -19.6% | -33.7% |
| 3-Month Price Change | -8.5% | +8.3% |
| 52-Week Range | ₹325.00 – ₹647.80 | ₹344.45 – ₹678.95 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹376 Cr | ₹833 Cr |
| Quarterly Net Profit | ₹103 Cr | ₹32 Cr |
| Net Margin | 27.3% | 3.9% |
| EPS (Basic, Quarter) | ₹5.46 | ₹0.80 |
| Results Basis | standalone | consolidated |
| Headquarters | Thane, Maharashtra | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and …
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, i…
Syngene International has a market capitalisation of ₹16,439 Cr, against ₹9,353 Cr for Blue Jet Healthcare as of 9 Nov 2026, about 1.8 times the size by market cap.
Blue Jet Healthcare has a P/E of 34.6 and Syngene International a P/E of 52.5 as of 9 Nov 2026.
Blue Jet Healthcare has a return on equity of 19.88% and Syngene International 6.62%.
Blue Jet Healthcare's share price is down 19.6% over one year and Syngene International's is down 33.7%.
Blue Jet Healthcare reported revenue of ₹376 Cr and net profit of ₹103 Cr for Q2 FY27. Syngene International reported revenue of ₹833 Cr and net profit of ₹32 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.